

November 12, 2022

To,  
Corporate Relations Department  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001.

Security Code: 540788

Security ID: ASPIRA

Sub: Outcome of Board Meeting

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI Listing Regulations, we wish to inform that the Board of Directors of the Company, at their meeting held today i.e **Saturday, November 12, 2022 (Commenced at 3:30 p.m. and concluded at 4:30 p.m.)**, *inter-alia*, considered and approved:

- 1) Un-audited Financial Results of the Company for the quarter and half yearly ended **September 30, 2022.**


Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, a copy of the 'Results' along-with Limited Review Report of the Statutory Auditors of the Company, are enclosed herewith.

- 2) Change in Designation of Mr. Arvind Bhanushali (DIN: 00011903) from Executive Director to Non-Executive Director on the Board of the Company with effect from November 12, 2022. Pursuant to SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, the disclosure as required is enclosed herewith **Annexure-A.**

The above is for your information and records.

Thanking you,

Yours Faithfully,  
For Aspira Pathlab & Diagnostics Limited



Priya Pandey  
Company Secretary & Compliance Officer  
Encl: As above





**P KHETAN & CO**  
Chartered Accountants

Office : B-208, Kukreja Centre,  
Plot-13, Sector- 11  
CBD Belapur, Navi Mumbai,  
Mumbai – 400614  
Mobile- 9821376512  
e-mail- [khetanpk@gmail.com](mailto:khetanpk@gmail.com)

**Independent Auditor's Review Report on unaudited quarterly and year to date financial results of Aspira Pathlab & Diagnostics Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report**

**To The Board of Directors**

**Aspira Pathlab & Diagnostics Limited**

We have reviewed the accompanying statement of **Unaudited Financial Results of Aspira Pathlab & Diagnostics Limited** ("the Company") for the quarter ended September 30, 2022 and the year to date results for the period April 01, 2022 to September 30, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR Regulation") including relevant circulars issued by the SEBI from time to time.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place- Mumbai  
Date- 12.11.2022

For **P Khetan & Co**  
Chartered Accountant  
Firm Reg. No. 327386E

*Pankaj Khetan*

Pankaj Kumar Khetan  
Partner

Membership No.- 066080  
UDIN: 22066080BCXOZM5563



**ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar ( W), Mumbai -400086  
Tel No. 022-71975756, Email :support@aspiradiagnostics.com,Website : www.aspiradiagnostics.com

Unaudited Financial Results for the Quarter and Six months ended 30th September, 2022

(Rupees in Lakhs)

Particulars	Quarter ended			Six Months ended		Year ended
	30-Sep-22 (Unaudited)	30-Jun-22 (Unaudited)	30-Sep-21 (Unaudited)	30-Sep-22 (Unaudited)	30-Sep-21 (Unaudited)	31-Mar-22 (Audited)
<b>1. Income</b>						
(a) Revenue from Operations	370.88	296.70	349.06	667.58	937.44	1,954.19
(b) Other Income	6.69	6.49	2.34	13.18	4.55	10.29
<b>Total Income</b>	<b>377.57</b>	<b>303.19</b>	<b>351.39</b>	<b>680.76</b>	<b>941.99</b>	<b>1,964.48</b>
<b>2. Expenses</b>						
(a) Cost of Materials consumed	69.15	53.42	63.80	122.56	138.68	313.81
(b) Laboratory Testing Charges	14.02	10.84	24.19	24.86	93.58	119.66
(c) Employee benefits expense	135.56	131.81	121.70	267.37	236.28	501.95
(d) Finance Costs	10.90	10.91	6.85	21.81	13.94	37.27
(e) Depreciation and amortisation expense	40.03	41.91	38.25	81.94	76.00	163.57
(f) Other expenses	106.41	82.83	82.14	189.24	168.71	382.27
<b>Total Expenses</b>	<b>376.06</b>	<b>331.71</b>	<b>336.93</b>	<b>707.77</b>	<b>727.19</b>	<b>1,518.53</b>
<b>3. Profit / (Loss) before exceptional items and tax (1-2)</b>	<b>1.51</b>	<b>(28.52)</b>	<b>14.46</b>	<b>(27.01)</b>	<b>214.80</b>	<b>445.94</b>
4. Exceptional Items	-	-	-	-	-	-
<b>5. Profit / (Loss) before tax (3+4)</b>	<b>1.51</b>	<b>(28.52)</b>	<b>14.46</b>	<b>(27.01)</b>	<b>214.80</b>	<b>445.94</b>
6. Tax Expenses	-	-	-	-	-	-
<b>7. Profit / (Loss) after tax (5-6)</b>	<b>1.51</b>	<b>(28.52)</b>	<b>14.46</b>	<b>(27.01)</b>	<b>214.80</b>	<b>445.94</b>
8. Other Comprehensive income (net of tax)	-	-	-	-	-	1.55
<b>9. Total Comprehensive income/ (Loss) (7+8)</b>	<b>1.51</b>	<b>(28.52)</b>	<b>14.46</b>	<b>(27.01)</b>	<b>214.80</b>	<b>447.49</b>
10. Paid up Equity share capital ( face value of Rs.10 each)	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30
11. Other Equity	-	-	-	-	-	249.65
<b>12. Earning per share (in Rupees)</b>						
(a) Basic	0.01	(0.28)	0.14	(0.26)	2.09	4.33
(b) Diluted	0.01	(0.28)	0.14	(0.26)	2.09	4.33

**Notes**

- The above unaudited financial results of the Company for the quarter and six months ended September 30, 2022 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 12th November, 2022.
- The above unaudited financial results for the quarter and six month ended September 30, 2022 has been subjected to limited review by statutory auditors of the Company and not subjected to audit. The auditors have expressed an unmodified opinion in the limited review report for the quarter and six months ended September 30, 2022.
- These unaudited financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.
- The above unaudited financial results for the six month ended September 30, 2022 are not comparable with the unaudited financial results for the six month ended September 30, 2021, due to resurgent wave of COVID-19 during the quarter ended June 30, 2021.
- The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect is yet to be notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact after the Code becomes effective.
- The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Dr. Pankaj J. Shah  
Managing Director  
DIN 02836324  
Place : Mumbai  
Date : 12.11.2022



ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN : L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar ( W), Mumbai -400086

Tel No. 022-71975756, Email : support@aspiradiagnostics.com, Website : www.aspiradiagnostics.com

Balance Sheet as at 30 September 2022

(Rupees in Lakhs)

Particulars	As at	
	30 September 2022 (un-audited)	31 March 2022 (Audited)
<b>A ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	355.95	387.62
Right of Use Assets	252.19	294.81
Goodwill	265.18	265.18
Other Intangible assets	7.32	9.74
Financial Assets		
(i) Loans and advances	112.94	108.21
(ii) Others	37.43	33.56
Deferred tax assets (net)	-	-
Other Non-current assets	-	-
<b>Total non-current assets</b>	<b>1,031.02</b>	<b>1,099.11</b>
<b>Current Assets</b>		
Inventories	43.89	40.45
Financial Assets		
(i) Trade Receivables	229.38	449.11
(ii) Cash and Cash Equivalents	145.74	135.44
(iii) Bank balances other than (ii) above	231.93	28.93
(iv) Others financial assets	2.91	4.94
Current tax assets (net)	42.79	46.41
Other Current Assets	26.97	9.15
<b>Total Current Assets</b>	<b>723.60</b>	<b>714.42</b>
<b>Total Assets</b>	<b>1,754.62</b>	<b>1,813.53</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity share Capital	1,029.30	1,029.30
Other equity	222.63	249.65
<b>Total Equity</b>	<b>1,251.93</b>	<b>1,278.95</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
(i) Borrowings	91.02	85.87
(ii) Lease liabilities	205.17	241.59
Provisions	33.35	28.25
<b>Total non-current liabilities</b>	<b>329.55</b>	<b>355.71</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Borrowings		
(ii) Lease liabilities	64.62	64.72
(iii) Trade payables	49.86	60.96
(iv) Other financial liabilities	46.62	42.25
Other current liabilities	10.68	9.97
Provisions	1.36	0.97
<b>Total current liabilities</b>	<b>173.14</b>	<b>178.87</b>
<b>Total Liabilities</b>	<b>502.69</b>	<b>534.58</b>
<b>Total Equity and Liabilities</b>	<b>1,754.62</b>	<b>1,813.53</b>

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Dr. Pankaj J. Shah  
Managing Director  
DIN: 02836324  
Place : Mumbai  
Date : 17.11.2022



**ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar ( W), Mumbai -400086

Tel No. 022-71975756, Email :support@aspiradiagnostics.com,Website : www.aspiradiagnostics.com

**Cash flow Statement for the half year ended 30th September 2022**

(Rupees in Lakhs)

Particulars	For the period ended	For the period ended
	30.09.2022	30.09.2021
	( Un-Audited)	( Un-Audited)
<b>A CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit/(Loss) for the year	(27.01)	214.80
Adjustments for:		
Interest income	(13.18)	(4.55)
Finance Costs	21.81	13.94
Depreciation and amortisation expenses	81.94	76.00
Provision for doubtful debts	(5.00)	8.64
<b>CASH GENERATED BEFORE WORKING CAPITAL CHANGES</b>	<b>58.55</b>	<b>308.83</b>
Adjustments for:		
(Increase)/Decrease in Trade receivables	224.73	(76.11)
(Increase)/Decrease in Inventories	(3.44)	(11.87)
(Increase)/Decrease in Current Security deposits and others	(2.70)	(1.26)
(Increase)/Decrease in Financial assets-Loans and advances	(206.87)	(41.90)
(Increase)/Decrease in other current assets	(14.21)	(2.52)
(Increase)/Decrease in Financial assets-others	-	(171.20)
(Increase)/Decrease in current tax assets(net)	-	(3.44)
Increase/(Decrease) in Trade payables	(11.10)	2.95
Increase/(Decrease) in Provisions	5.50	6.17
Increase/(Decrease) in short term borrowings	-	(48.39)
Increase/(Decrease) in other Current Liabilities	0.70	7.88
Increase/(Decrease) in Other financial liabilities	4.37	(0.29)
<b>CASH GENERATED FROM OPERATIONS</b>	<b>55.53</b>	<b>(31.14)</b>
Taxes Paid ( net of refunds)	-	-
<b>NET CASH (USED IN)/ GENERATED FROM OPERATING ACTIVITIES(A)</b>	<b>55.53</b>	<b>(31.14)</b>
<b>B CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of property , plant and equipment	(9.42)	(29.70)
Purchase of Intangible assets	(0.50)	(0.10)
Interest Received	13.18	4.55
<b>NET CASH FLOW (USED IN)/ GENERATED FROM INVESTING ACTIVITIES - (B)</b>	<b>3.26</b>	<b>(25.26)</b>
<b>C CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Long term borrowings	5.15	4.60
Repayment of long term borrowings	-	-
Repayment of Lease Liability	(31.83)	(27.06)
interest paid	(21.81)	(13.94)
<b>NET CASH (USED IN)/ GENERATED FROM FINANCING ACTIVITIES (C)</b>	<b>(48.49)</b>	<b>(36.40)</b>
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	10.30	(92.80)
Add:Cash and Cash Equivalents at the beginning of the year	135.44	118.77
<b>Cash and Cash Equivalents at the end of the year</b>	<b>145.74</b>	<b>25.97</b>
<b>Components of cash and cash equivalents comprise:</b>		
Cash in hand	23.70	6.12
Balances with banks:		
-In Current Accounts	121.99	19.81
-In Escrow Account	0.05	0.04
<b>Cash and Cash Equivalents in cash flow statement</b>	<b>145.74</b>	<b>25.97</b>

**Note:**

- 1) Cash and Cash equivalents represents cash in hand and balances with banks and Overdraft Facilities.
- 2) The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard (Ind AS) 7 Statement of Cash Flows.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Dr. Pankaj J. Shah  
Managing Director  
DIN. 02836324  
Place : Mumbai  
Date : 12.11.2022



Disclosure of information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. no.	Particulars	Disclosure
1.	Name of Director	Mr. Arvind Bhanushali (DIN: 00011903)
2.	Reason of Change	Change in Designation of Mr. Arvind Bhanushali (DIN: 00011903) from the Executive Director to Non-Executive Director of the Company with effect from November 12, 2022 whose period of office shall be determined as director liable to retire by rotation.
3.	Date of appointment/cessation/ change in designation	12 <sup>th</sup> November, 2022 from the Executive Director to Non-Executive Director of the Company
4.	Brief Profile	Not Applicable
5.	Disclosure of relationships between Directors	Not Applicable